|
Corporate Profile
Affymax, Inc. is a clinical-stage biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematideā¢, is currently entering Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase 2 clinical trials for the treatment of anemia in cancer patients.
Webcasts
May 21, 2008
2008 Citi Investment Research Global Health Care Conference
Recent Press Releases
May 9, 2008
Affymax(R) Reports First Quarter 2008 Financial Results
Apr 22, 2008
Affymax Announces Upcoming Webcasts and Conference Participation
|